Nefopam/Paracetamol Fixed Dose Combination in Acute Pain After Impacted Third Molar Extraction

Last updated: November 20, 2024
Sponsor: Unither Pharmaceuticals, France
Overall Status: Completed

Phase

3

Condition

Acute Pain

Pain

Treatment

Paracetamol 500 Mg Oral Tablet X2

Nefopam HCl 30 MG Oral Tablet X2

nefopam hydrochloride 30mg / paracetamol 500mg X2

Clinical Study ID

NCT04622735
UP-CLI-2019-002
  • Ages 18-65
  • All Genders

Study Summary

This study aims to evaluate the analgesic efficacy of single and multiple doses of a new fixed dose combination of nefopam hydrochloride 30 mg and paracetamol 500mg taken orally in comparison to each single component.

Eligibility Criteria

Inclusion

Main Inclusion Criteria:

  • Male and female patient aged from 18 years up to 65 years,

  • Patient scheduled to undergo the surgical removal of at least one fully or partiallyimpacted third mandibular molar requiring bone removal under short-acting localanaesthetic (mepivacaine or lidocaine) with or without vasoconstrictor,

  • Patient weighing > 50 kg,

  • Patient who has signed a written informed consent prior to any study-relatedprocedures.

Additional inclusion criteria after surgery (randomization):

  1. Patient experiencing moderate to severe pain within 4 hours after the dentalextraction, defined by a baseline pain intensity Visual Analogic Scale (VAS) score ≥ 50 mm,

  2. Third molar extraction(s) completed without any immediate complication, that in theopinion of the investigator, would interfere with the study conduct and/orassessments (e.g., suspected neurosensory complication, incomplete removal of tooth)

Exclusion

Main Exclusion Criteria:

  • Patient treated by analgesics or nonsteroidal anti-inflammatory drugs (NSAIDs)within 3 days preceding the day of randomization or within 5 times the eliminationhalf-life whichever the longest,

  • Woman with positive results on a urine pregnancy test or breastfeeding woman orwoman of childbearing potential without an effective contraception,

  • Patient with a history of convulsive disorders,

  • Patient taking mono-amine-oxidase (MAO) inhibitors (including but not limited toselegiline, isocarboxazid, tranylcypromine, phenelzine...),

  • Patient with an abnormal cardiac condition: medically significant disorders ofcardiac rate and/or rhythm,

  • Patient with known anaemia,

  • Patient with known pulmonary disease,

  • Patient with known active gastric or duodenal ulcer or a history of recurrentgastrointestinal ulcer/bleeding,

  • Patient with known glaucoma,

  • Patients with a prostatic hyperplasia or urinary retention,

  • Patient with current or chronic history of liver disease, or known hepatic orbiliary abnormalities,

  • Patient with a current or chronic history of severe renal impairment (glomerularfiltration below 30 mL/min),

Study Design

Total Participants: 321
Treatment Group(s): 3
Primary Treatment: Paracetamol 500 Mg Oral Tablet X2
Phase: 3
Study Start date:
February 22, 2020
Estimated Completion Date:
October 20, 2022

Connect with a study center

  • Hôpital Erasme- ULB- Bruxelles

    Bruxelles,
    Belgium

    Site Not Available

  • Hôpital Leuven

    Leuven,
    Belgium

    Site Not Available

  • CH Amiens

    Amiens, 80054
    France

    Site Not Available

  • CHU Angers

    Angers, 49933
    France

    Site Not Available

  • Ch Boulogne

    Boulogne,
    France

    Site Not Available

  • CHU Marseille

    Marseille, 13385
    France

    Site Not Available

  • Centre Hospitalier de Pontoise

    Pontoise, 95300
    France

    Site Not Available

  • HIA Toulon

    Toulon, 83800
    France

    Site Not Available

  • CHU de tours

    Tours, 37170
    France

    Site Not Available

  • Clinexpert Kft.

    Budapest,
    Hungary

    Site Not Available

  • Óbudai Egészségügyi Centrum

    Budapest,
    Hungary

    Site Not Available

  • Swan-Med Kft.

    Letavertes,
    Hungary

    Site Not Available

  • Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókórház,

    Nyíregyháza,
    Hungary

    Site Not Available

  • SmileDent Kft.

    Szeged,
    Hungary

    Site Not Available

  • Szent Borbála Kórház,

    Tatabánya,
    Hungary

    Site Not Available

  • Óbudai Egészségügyi Centrum

    Zalaegerszeg,
    Hungary

    Site Not Available

  • LLC Center for interdisciplinary dentistry & neuro

    Moscow, 141207
    Russian Federation

    Site Not Available

  • State Medico-stomato Univ., by A.I. Evdokimov

    Moscow,
    Russian Federation

    Site Not Available

  • Regional clinical hospital

    Yaroslavl, 150062
    Russian Federation

    Site Not Available

  • Birmingham School of Dentistry

    Birmingham, B5 7EG
    United Kingdom

    Site Not Available

  • University Dental Hospital

    Cardiff, CF14 4XY
    United Kingdom

    Site Not Available

  • Edinburgh Dental Institute

    Edinburgh, EH3 9HX
    United Kingdom

    Site Not Available

  • BARTS HEALTH NHS TRUST Royal London Hospital

    London, E1 1FR
    United Kingdom

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.